|
|
||||||||
Departments of 1 Physiology and Biophysics and 2 Nutrition, Case Western Reserve University, Cleveland, Ohio 44106-4970; and 3 Department of Nutrition, University of Montreal, Montreal, Quebec H3C 3Y7, Canada
| |
ABSTRACT |
|---|
|
|
|---|
In the well-perfused heart, pyruvate carboxylation accounts for 3-6% of the citric acid cycle (CAC) flux, and CAC carbon is lost via citrate release. We investigated the effects of an acute reduction in coronary flow on these processes and on the tissue content of CAC intermediates. Measurements were made in an open-chest anesthetized swine model. Left anterior descending coronary artery blood flow was controlled by a extracorporeal perfusion circuit, and flow was decreased by 40% for 80 min to induce myocardial hibernation (n = 8). An intracoronary infusion of [U-13C3]lactate and [U-13C3]pyruvate was given to measure the entry of pyruvate into the CAC through pyruvate carboxylation from the 13C-labeled isotopomers of CAC intermediates. Compared with normal coronary flow, myocardial hibernation resulted in parallel decreases of 65% and 79% in pyruvate carboxylation and net citrate release by the myocardium, respectively, and maintenance of the CAC intermediate content. Elevation of the arterial pyruvate concentration by 1 mM had no effect. Thus a 40% decrease in coronary blood flow resulted in a concomitant decrease in pyruvate carboxylation and citrate release as well as maintenance of the CAC intermediates.
cardiac; citric acid cycle; dehydrogenase; metabolism; ischemia
| |
INTRODUCTION |
|---|
|
|
|---|
THE
HIBERNATING MYOCARDIUM is defined by reversible myocardial
contractile dysfunction due to reduced coronary flow and decreased oxygen supply to the myocardium (26). The hallmarks of
hibernation are the retention of viable myocardial tissue with residual
mitochondrial functions such as pyruvate and fatty acid oxidation,
electron-transport-chain flux, and oxidative phosphorylation to
generate ATP (1, 29). Little is known about the function
of the citric acid cycle (CAC) in myocardium during hibernation.
Ischemia in isolated perfused rat hearts causes an increase in
the net efflux of the CAC intermediate succinate (15, 24,
25). Although this suggests a net loss of CAC intermediates
during ischemia, it is not clear whether ischemia
results in depletion of the pool of CAC intermediates (11, 15,
24). The tissue content of CAC intermediates is small compared
with the flux through the cycle, and loss of CAC intermediates from the
cycle must be balanced by the entry of intermediates into the CAC if
the pool size is to be maintained (see Fig.
1). With normal myocardial blood flow,
the loss of CAC intermediates is balanced by the entry of newly
synthesized intermediates into the cycle; this process is termed
anaplerosis (7, 8, 11, 14, 21). The effects of acute
myocardial hibernation on the rate of anaplerosis and the tissue
content of CAC intermediates are not known.
|
Pyruvate carboxylation is a major anaplerotic pathway in normal
myocardium in vivo (21) and generates malate and
oxaloacetate (OAA) via malic enzyme and pyruvate carboxylase,
respectively (2, 8, 23, 35, 36) (see Fig. 1). We recently
developed a method to measure in the heart of anesthetized swine the
rate of pyruvate carboxylation and decarboxylation using
[U-13C3]lactate and
[U-13C3]pyruvate tracers and mass isotopomer
analysis of tissue pyruvate and citrate (21). In isolated
rat hearts and in vivo swine myocardium, we found that pyruvate
carboxylation accounted for 2.5-8% of the citrate synthase flux
(7, 8, 21, 39). We also found that the rate of pyruvate
carboxylation was not significantly altered when the rate of pyruvate
decarboxylation (i.e., flux through pyruvate dehydrogenase) was
inhibited by >90% by infusion of octanoate. Thus constitutive
pyruvate carboxylation appears to be essential for normal cardiac
function as was demonstrated in isolated working rat hearts where there
was a dramatic fall in ventricular power when pyruvate carboxylation
was pharmacologically inhibited (28). Constitutive
pyruvate carboxylation balances the loss of CAC intermediates
(11, 15, 21, 39) including citrate (21, 39).
Under aerobic conditions, citrate efflux from rat, swine, and human
hearts ranges from 5 to 20 nmol · g
1 · min
1 (21,
38, 39). Net citrate efflux from swine myocardium amounts to
~20% of the rate of pyruvate carboxylation (21).
The extent of pyruvate carboxylation and citrate efflux in the hibernating or ischemic myocardium is not known. Opie (20) reported a 33% decrease in myocardial citrate content after 30 min of severe ischemia (an ~90% reduction in flow) in dogs; however, the actual rate of citrate efflux from the heart was not measured. Evidence for a role of CAC intermediate depletion in postischemic cardiac dysfunction was suggested by improved postischemic functional recovery when anaplerotic substrates (pyruvate, glutamate, or propionate) were administered to isolated rodent hearts (4, 6, 27, 28, 37). The functional benefits of elevated pyruvate concentration suggest that anaplerotic pyruvate carboxylation may play an important role in the correction of metabolic abnormalities during conditions of stress such as hibernation.
The goals of the present study were to: 1) examine the effects of hibernation on the content of CAC intermediates in the heart; 2) measure pyruvate carboxylation, pyruvate decarboxylation, and citrate efflux in the myocardium during hibernation; and 3) determine the effects of pharmacological concentrations of pyruvate on the hibernating myocardium. We used [U-13C3] lactate and [U-13C3]pyruvate and isotopomer analysis of tissue pyruvate and citrate to measure pyruvate carboxylation and decarboxylation in the well-characterized swine model of acute myocardial hibernation (1, 18, 29).
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Chemicals. Chemicals, enzymes, and coenzymes were purchased from Boehringer Mannheim (Indianapolis, IN) and Sigma-Aldrich (Milwaukee, WI). [2H6]succinic acid, [U-13C3] lactate, and [U-13C3]pyruvate were obtained from Isotec (Miamisburg, OH). The derivatization agent N-methyl-N-(tert-butyldimethylsilyl)trifluoroacetamide was supplied by Regis Chemical (Morton Grove, IL). Intralipid solution was obtained from Baxter Healthcare (Deerfield, IL).
Experimental model.
A previously described in vivo technique was used to deliver
13C-labeled substrates directly into the left anterior
descending (LAD) coronary artery of swine (31, 32).
Overnight-fasted domestic swine (weight 27-38 kg) of either sex
were sedated with Telazol (6 mg/kg im), anesthetized with pentobarbital
sodium (25 mg/kg + 5 mg · kg
1 · h
1 iv),
intubated via a tracheotomy, and ventilated to maintain arterial blood
gas values in the normal range (PO2 > 100 mmHg, PCO2 of 35-45 mmHg, and pH of
7.35-7.45). A 7-Fr high-fidelity pressure transducer catheter
(Millar; Houston, TX) was positioned in the left ventricle via the
carotid artery. The animal was then heparinized (300 U/kg bolus + 150 U · kg
1 · h
1 iv) and
infused with a 20% triglyceride emulsion (Intralipid 20%, 0.3 ml · kg
1 · h
1 iv) to
increase plasma free fatty acids (FFA) to 0.6 mM (32). Coronary blood flow in the anterior wall was controlled by an extracorporeal circuit as previously described (31, 32).
The anterior interventricular vein was cannulated to collect venous blood samples from the perfusion territory of the LAD. The coronary perfusion pump flow was adjusted to give an interventricular venous Hb
saturation of 35-40% (31, 32).
Experimental protocols.
Pigs were subjected to acute myocardial hibernation induced by
decreasing the blood flow to the LAD bed by 40% (see Fig.
2). Pyruvate carboxylation and
decarboxylation were measured with an intracoronary infusion of
[U-13C3]lactate and/or
[U-13C3]pyruvate for 60 min, with subsequent
analysis of myocardial tissue for 13C isotopomers of
pyruvate and CAC intermediates by gas chromatography-mass spectrometry
(GC-MS) as previously described (21). Stock solutions of
99% [U-13C3]lactate and/or 99%
[U-13C3]pyruvate were directly infused into
the LAD perfusion circuit at a rate of 6.5 µl/ml of LAD blood flow
(see Fig. 2). Pyruvate carboxylation was measured in hibernating
myocardium under either near-normal arterial lactate and pyruvate
concentrations (HIB group, n = 8), or with elevated
arterial pyruvate concentration (HIB + PYR group,
n = 8). In HIB animals, the concentrations of [U-13C3]lactate and
[U-13C3]pyruvate in the infusate were 154 and
15.4 mM, respectively, so that the lactate and pyruvate concentrations
in LAD blood were raised by 1.0 and 0.1 mM, respectively. In the
HIB + PYR group, the concentration of
[U-13C3]pyruvate in the infusate was 154 mM,
so that the pyruvate concentration in LAD blood was raised by 1.0 mM.
Left ventricular pressure, end-diastolic pressure, peak first
derivative of left ventricular (LV) pressure with time
(dP/dt), heart rate, and arterial and venous blood samples
were taken at all sample times (see Fig. 2). Plasma samples were stored
at
80°C until further analysis. At the end of each protocol, large
punch biopsies (3 g) of the LAD and circumflex (CFX) beds were quickly
taken, freeze-clamped, and stored at
80°C until analysis. We have
previously shown that the CFX biopsy receives normal myocardial blood
flow and thus serves as control tissue (18, 31). The heart
was excised, and black ink was infused down the right and left main
coronary arteries to identify the LAD perfusion bed, which was
dissected and weighed (37.1 ± 2.7 g).
|
Analytic methods. The concentrations of plasma FFA, blood glucose, lactate, pyruvate, and citrate, as well as tissue lactate, pyruvate, and malate were determined using spectrophotometric enzymatic assays (3, 33, 40). Tissue pyruvate concentrations were measured immediately after homogenization in neutralized perchloric acid extracts to prevent loss of pyruvate from freeze-thaw (40). Tissue concentrations of ATP and ADP were measured using the ATP Bioluminescent Assay Kit (Sigma-Aldrich).
Isotopic enrichments of plasma lactate and pyruvate were determined from the GC-MS analysis of the corresponding tert-butyldimethylsilyl (TBDMS) derivatives as previously described (7, 8, 21). The mass isotopomer distribution of tissue lactate, pyruvate, citrate, succinate, fumarate, and malate and the OAA moiety of citrate were also assayed as TBDMS derivatives (7, 8, 15, 39). Analyses were performed on a Hewlett-Packard 5890 Series II GC with an HP-5 capillary column (length 50 m, inside diameter 0.2 mm, and film thickness 0.3 µm) coupled to a mass-selective detector (model 5970). Helium gas flow in the capillary column was 0.8-1.0 ml/min. Individual enrichments are averages of two or three GC-MS injections. The tissue concentrations of citrate, succinate, and fumarate were also assayed by GC-MS as previously described (7, 21). Enzyme activity of malic enzyme was measured using the methods described by Lin and Davis (17). Activity of pyruvate carboxylase was measured as per a modification of the original method by Struck and colleagues (34).Calculations.
The myocardial blood flow was calculated as the LAD perfusion pump flow
divided by the mass of the LAD perfusion bed. Mass isotopomers of
metabolites containing 0-n 13C atoms are
identified as Mi, where i = 0, 1,...,n. The relative rates of pyruvate carboxylation and
decarboxylation were calculated as previously described
(7) from 1) the M3 enrichment of tissue pyruvate, and 2) the M2 and M3 enrichments of the acetyl-CoA
and OAA moieties of citrate, respectively (21). Mass
isotopomers were adjusted for the natural abundance measured in
myocardial tissue samples from pigs (n = 4) that were
not infused with labeled substrates (5, 9). The measured
enrichment of the M3 OAA moiety of citrate was corrected for
1) the fraction of M3 OAA molecules coming from some citrate
isotopomers metabolized in the CAC and 2) the dilution of
13C in the CAC, as described in detail by Comte and
co-workers (Eqs. 8-10 in Ref.
7). The absolute rates of pyruvate carboxylation and
decarboxylation were calculated from the relative rates of pyruvate
carboxylation and decarboxylation and the absolute rate of CAC flux.
The latter was calculated from the myocardial oxygen consumption
(M
O2) and the stoichiometric
relationships between oxygen consumption and citrate formation from fat
and carbohydrate as previously described (21).
Statistical analysis. Data are presented as means ± SE. The hemodynamic variables were compared between the two protocols using repeated-measures ANOVA. Statistical significance was determined using paired and unpaired t-tests as appropriate.
| |
RESULTS |
|---|
|
|
|---|
Cardiovascular parameters.
There were no significant changes over the course of the experiment or
between groups at any time point in peak systolic LV pressure, peak LV
dP/dt, heart rate (see Fig.
3), or LV end-diastolic pressure (data
not shown). In the HIB and HIB + PYR groups,
M
O2 decreased by ~38% after 80 min of
flow reduction (see Fig. 3).
|
Metabolite concentrations and enrichments.
With the onset of flow reduction, there was a metabolic switch from net
lactate uptake to lactate production (see Fig.
4).
|
1 · min
1 for HIB
and HIB + PYR groups, respectively) to the hibernation period
(2.5 ± 2.3 and 1.4 ± 2.1 nmol · g
1 · min
1 for HIB
and HIB + PYR groups, respectively) in both the HIB and HIB + PYR groups. The rate of citrate release during hibernation was
significantly lower than our previously published values
(21) from animals subjected to the same isotope infusion
but with normal coronary blood flow (see Fig.
5). Thus myocardial hibernation resulted
in an ~80% reduction in citrate release by the heart.
|
1 · min
1 for the
HIB and HIB + PYR animals, respectively, and were not different at
the end of the protocol (0.09 ± 0.01 and 0.09 ± 0.03 µmol · g
1 · min
1 for the
HIB and HIB + PYR groups, respectively). The rates of glucose
uptake were similar at the end of the protocol compared with the
equilibration period for the HIB animals (0.31 ± 0.06 and
0.51 ± 0.20 µmol · g
1 · min
1,
respectively) and the HIB + PYR animals (0.26 ± 0.04 and
0.47 ± 0.19 µmol · g
1 · min
1, respectively).
Tissue metabolites.
Tissue lactate and pyruvate content and the lactate-to-pyruvate ratio
were similar between the two groups (see Table
1) and were not different from previously
published values from normal-flow animals subjected to the same
isotope-infusion protocol (21). Thus despite lactate
production at the onset of flow reduction, we observed normal lactate
and lactate-to-pyruvate ratios after 80 min of reduced flow.
Furthermore, the concentrations of ATP and ADP and the ATP-to-ADP ratio
were unchanged between the hibernating LAD and CFX beds or between the
two groups for a given bed (see Table 2),
which confirms the observation of Schulz et al. (29) that
there are normal ATP levels after ~80 min of moderate flow reduction
in swine myocardium.
|
|
|
Pyruvate carboxylation and decarboxylation.
The relative rates of pyruvate decarboxylation and carboxylation were
calculated as previously described (7, 21). There were no
changes in pyruvate decarboxylation between the groups (see Table
4) nor were these values different from
values obtained in aerobic hearts (21). The relative rates
of pyruvate carboxylation during hibernation were unaffected by
elevated arterial pyruvate concentrations; however, values from
hibernating myocardium were 50% lower than those previously found in
aerobic and aerobic + pyruvate animals (see Table 4). Because
there was not a significant change in pyruvate decarboxylation, the
ratio of carboxylation to decarboxylation was significantly decreased
by hibernation in both groups (see Table 4).
|
O2 as described previously
(21). The rates of CAC flux were similar between the two
groups (1.06 ± 0.08 and 1.14 ± 0.12 µmol · g
1 · min
1 for the
HIB and HIB + PYR groups, respectively). The absolute rates of
pyruvate decarboxylation (which is the flux through pyruvate dehydrogenase) were similar between the HIB and HIB + PYR groups (488 ± 44 and 457 ± 47 nmol · g
1 · min
1,
respectively) and our previously published values from aerobic myocardium (21). The absolute rates of pyruvate
carboxylation were again similar between the HIB and HIB + PYR
groups; however, these fluxes were decreased by 65% compared with
previously published data from aerobic and aerobic + pyruvate
animals (see Fig. 5) (21).
Analysis of the mass isotopomer distribution of the OAA moiety of
citrate and succinate allow one to calculate the fraction of the OAA
pool that is recycled after one turn of the CAC. The fraction that is
lost has two components: loss of CAC intermediates from the cell, and
isotopic exchanges between metabolites of the CAC and related compounds
such as glutamate, glutamine, and aspartate. In the present
investigation, the extent of recycling of citrate through the CAC was
72 ± 3 and 70 ± 4% for the HIB and HIB + PYR animals,
respectively. These are significantly higher than our previously
published values obtained during normal flow aerobic conditions
(60 ± 4% and 56 ± 4% for normal and high-pyruvate
conditions, respectively). Thus there is greater recycling of CAC
carbon during hibernation as confirmed by the decrease in citrate
release (see Fig. 5).
Malic enzyme and pyruvate carboxylase activity.
Owing to the lower rate of pyruvate carboxylation in hibernating
myocardium, we examined the possibility that there was a decrease in
the activity of malic enzyme and/or pyruvate carboxylase. The activity
of malic enzyme was unchanged between the LAD perfusion bed (840 ± 50 nmol · g
1 · min
1) and
the CFX bed (830 ± 50 nmol · g
1 · min
1) in the
HIB group. There was also no difference between the LAD and CFX beds in
the activity of pyruvate carboxylase (32 ± 7 and 31 ± 9 nmol · g
1 · min
1,
respectively) in the HIB group. Similar values were obtained in the
HIB + PYR group.
| |
DISCUSSION |
|---|
|
|
|---|
The key finding of this study is that a 40% reduction in
M
O2 results in a decrease in both
pyruvate carboxylation and citrate efflux with the maintenance of
tissue levels of CAC intermediates. The absolute rate of pyruvate
carboxylation decreased by 65% when there was only a 38% drop in
M
O2 (see Fig. 3). If the decrease in
malate and/or OAA supply to the CAC via pyruvate carboxylation were not
matched by a decrease in the rate of the net efflux of CAC
intermediates from the cycle, then the concentration of CAC intermediates in the myocardium would decrease. Hibernation had no
effect on the tissue contents of citrate, succinate, fumarate, or
malate, which suggests that the decrease in citrate release reflects a
decrease in other efflux pathways for CAC intermediates, thus
preserving the integrity of the CAC and the production of reducing
equivalents, electron-transport-chain flux, and ATP formation, albeit
at decreased rates.
An acute reduction in coronary blood flow of ~40% results in an
initial acceleration of glycolysis, a decrease in ATP, and a subsequent
resetting of the metabolism to better match the reduced oxygen supply
(1, 10, 22, 29). After 60-90 min of coronary blood
flow reduction, the myocardium is in a relative state of hibernation
with restored ATP content and reduced lactate production (1, 10,
29). The results of the present investigation extend the
understanding of the acute phase of myocardial hibernation and
demonstrate that the heart adjusts its metabolism to maintain the
tissue content of CAC intermediates by a decrease in pyruvate carboxylation and citrate release. Thus the mitochondria conserve the
constituents of the CAC. This is reflected in the greater degree of
carbon recycling in the CAC as assessed by mass isotopomer analysis. It
is important to note that prolonged hibernation may result in impaired
CAC function, as recently suggested by Schulz and colleagues
(30), who observed a progressive decrease in M
O2 during the course of 24 h of
hibernation (an ~40% reduction in LAD flow) in a similar swine model.
It has been suggested that with reduced coronary blood flow the rate of
anaplerosis does not match the rate of CAC intermediate efflux, and
there is a significant depletion of CAC intermediates (11). This is clearly not the case in acutely hibernating
swine myocardium (see Table 3). As noted above, the decrease in
anaplerotic pyruvate carboxylation matched with a decrease in net
citrate efflux suggests that the CAC intermediate release is balanced by anaplerosis during hibernation. We measured net citrate efflux values from the heart of 2.5 and 1.4 nmol · g
1 · min
1, which
account for 10% and 6% of the absolute pyruvate carboxylation flux
for HIB and HIB + PYR animals, respectively. This suggests that a
decrease in the efflux of other metabolites such as succinate (15) plays a role in maintaining the total pool size of
CAC intermediates. It is important to note that net citrate release may
underestimate the true rate of citrate loss from the CAC. Cytosolic
ATP-citrate lyase could cleave citrate into OAA and acetyl-CoA
(12); therefore citrate loss from the CAC may be greater
than the net citrate release and account for a larger fraction of the
pyruvate carboxylation unless the carbon of OAA returns to the mitochondria.
Another possible site of release from the CAC is the decarboxylation of malate by malic enzyme (13). However, the energetics of the reaction toward decarboxylation are unfavorable (35), and ex vivo experiments suggest that malic enzyme is mainly a carboxylating enzyme (8, 36, 39). In addition, we observed no M1 labeling of pyruvate with either normal flow (21) or with hibernation, which indicates that malate was not being decarboxylated by malic enzyme to produce pyruvate.
Myocardial hibernation did not affect the relative contribution of pyruvate decarboxylation (via pyruvate dehydrogenase) to the CAC flux (see Table 4). This confirms the work of Liedtke (16), which used 14C-labeled substrate to demonstrate that a 60% reduction in LAD flow in swine decreases CAC flux but does not alter the relative contributions of fatty acids and carbohydrates to oxidative metabolism. This same observation was made using 13C-labeled glucose and NMR analysis in dogs subjected to a 30% reduction in coronary flow for 3-4 h (19). Thus with acutely hibernating myocardium, there is no change in the contribution of carbohydrate to oxidative metabolism.
The elevated pyruvate concentrations in the HIB + PYR group did not elicit an increase in tissue pyruvate, pyruvate decarboxylation, or pyruvate carboxylation (see Tables 1 and 4; Fig. 5) or an increase in tissue M3 enrichment of pyruvate (data not shown). The lack of effect of elevated arterial pyruvate may be attributed to a low uptake of pyruvate into the myocardium. Studies infusing pyruvate at higher concentrations (5 mM) have reported an increased contribution of pyruvate to citrate after ischemia and improved contractile function (6, 37). In this study, with an arterial pyruvate concentration of 1.21 mM, we did not see any effect of pyruvate on pyruvate carboxylation or decarboxylation compared with an arterial pyruvate concentration of 0.28 mM. Further experimentation will be necessary to determine whether higher arterial concentrations of pyruvate will increase the contribution of pyruvate to citrate during hibernation.
The present results suggest that there is a fine interregulation among the rates of CAC flux, pyruvate carboxylation, and release of CAC intermediates and the CAC pool size; however, the biochemical mechanisms are unclear. We did not observe a decrease in the in vitro activities of malic enzyme and/or pyruvate carboxylase, which suggests that there was not stable covalent modification of these enzymes, though it is possible that the effect of in vivo modification was lost when measured in vitro at near maximal activity. Hibernation does not appear to cause gross changes in some of the regulators of malic enzyme or pyruvate carboxylase such as pyruvate, NADP+/NADPH, ATP, ADP, malate, and acetyl-CoA (see Tables 1-3) (21, 32). Thus the biochemical mechanisms for the decrease in pyruvate carboxylation remain to be elucidated.
In conclusion, the acute hibernation response is accompanied by a decrease in both pyruvate carboxylation and citrate efflux and the maintenance of tissue levels of CAC intermediates. Thus the integrity of the CAC is maintained during the early phase of myocardial hibernation.
| |
ACKNOWLEDGEMENTS |
|---|
The authors thank Dr. D. Kerr and M. Lusk of the Department of Pediatrics, Case Western Reserve University for assistance with the pyruvate carboxylase assay and F. David and T. McElfresh for technical assistance in conducting this study.
| |
FOOTNOTES |
|---|
This work was supported by National Institutes of Health Grants HL-58653 (to W. C. Stanley), HL-59219 (to H. Brunengraber), and HL-07887, and Grant-in-Aid 005031N from the American Heart Association National Center (to W. C. Stanley).
Address for reprint requests and other correspondence: W. C. Stanley, Dept. of Physiology and Biophysics, School of Medicine, Case Western Reserve Univ., 10900 Euclid Ave. Cleveland, OH 44106-4970 (E-mail: WCS4{at}po.cwru.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 3 April 2001; accepted in final form 25 May 2001.
| |
REFERENCES |
|---|
|
|
|---|
1.
Arai, AE,
Pantely GA,
Anselone CG,
Bristow J,
and
Bristow JD.
Active downregulation of myocardial energy requirements during prolonged moderate ischemia in swine.
Circ Res
69:
1458-1469,
1991
2.
Attwood, PV.
The structure and the mechanism of action of pyruvate carboxylase.
Int J Biochem Cell Biol
27:
231-249,
1995[ISI][Medline].
3.
Bergmeyer, HU.
Method of Enzymatic Analysis: Metabolites 2. Weinhein: VCH Verlagsgesellschaft, 1989.
4.
Bittl, JA,
and
Shine KI.
Protection of ischemic rabbit myocardium by glutamic acid.
Am J Physiol Heart Circ Physiol
245:
H406-H412,
1983.
5.
Brunengraber, H,
Kelleher JK,
and
Des Rosiers C.
Applications of mass isotopomer analysis to nutrition research.
Annu Rev Nutr
17:
559-596,
1997[ISI][Medline].
6.
Bunger, R,
Mallet RT,
and
Hartman DA.
Pyruvate-enhanced phosphorylation potential and inotropism in normoxic and postischemic isolated working heart. Near-complete prevention of reperfusion contractile failure.
Eur J Biochem
180:
221-233,
1989[ISI][Medline].
7.
Comte, B,
Vincent G,
Bouchard B,
and
Des Rosiers C.
Probing the origin of acetyl-CoA and oxaloacetate entering the citric acid cycle from the 13C labeling of citrate released by perfused rat hearts.
J Biol Chem
272:
26117-26124,
1997
8.
Comte, B,
Vincent G,
Bouchard B,
Jette M,
Cordeau S,
and
Des Rosiers C.
A 13C mass isotopomer study of anaplerotic pyruvate carboxylation in perfused rat hearts.
J Biol Chem
272:
26125-26131,
1997
9.
Des Rosiers, C,
Di Donato L,
Comte B,
Laplante A,
Marcoux C,
David F,
Fernandez CA,
and
Brunengraber H.
Isotopomer analysis of citric acid cycle and gluconeogenesis in rat liver. Reversibility of isocitrate dehydrogenase and involvement of ATP-citrate lyase in gluconeogenesis.
J Biol Chem
270:
10027-10036,
1995
10.
Fedele, FA,
Gewirtz H,
Capone RJ,
Sharaf B,
and
Most AS.
Metabolic response to prolonged reduction of myocardial blood flow distal to a severe coronary artery stenosis.
Circulation
78:
729-735,
1988
11.
Gibala, MJ,
Young ME,
and
Taegtmeyer H.
Anaplerosis of the citric acid cycle: role in energy metabolism of heart and skeletal muscle.
Acta Physiol Scand
168:
657-665,
2000[ISI][Medline].
12.
Huang, WY,
and
Kummerow FA.
Cholesterol and fatty acid synthesis in swine.
Lipids
11:
34-41,
1976[ISI][Medline].
13.
Jeffrey, FM,
Storey CJ,
Sherry AD,
and
Malloy CR.
13C isotopomer model for estimation of anaplerotic substrate oxidation via acetyl-CoA.
Am J Physiol Endocrinol Metab
271:
E788-E799,
1996
14.
Kornberg, HL.
Anaplerotic sequences and their role in metabolism.
In: Essays in Biochemistry, edited by Campbell PN,
and Marshall RD.. London: Academic, 1966, p. 1-31.
15.
Laplante, A,
Vincent G,
Poirier M,
and
Des Rosiers C.
Effects and metabolism of fumarate in the perfused rat heart. A 13C mass isotopomer study.
Am J Physiol Endocrinol Metab
272:
E74-E82,
1997
16.
Liedtke, AJ.
Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart.
Prog Cardiovasc Dis
23:
321-336,
1981[ISI][Medline].
17.
Lin, RC,
and
Davis EJ.
Malic enzymes of rabbit heart mitochondria. Separation and comparison of some characteristics of a nicotinamide adenine dinucleotide-preferring and a nicotinamide adenine dinucleotide phosphate-specific enzyme.
J Biol Chem
249:
3867-3875,
1974
18.
Mazer, CD,
Cason BA,
Stanley WC,
Shnier CB,
Wisneski JA,
and
Hickey RF.
Dichloroacetate stimulates carbohydrate metabolism but does not improve systolic function in ischemic pig heart.
Am J Physiol Heart Circ Physiol
268:
H879-H885,
1995
19.
McNulty, PH,
Sinusas AJ,
Shi CQ,
Dione D,
Young LH,
Cline GC,
and
Shulman GI.
Glucose metabolism distal to a critical coronary stenosis in a canine model of low-flow myocardial ischemia.
J Clin Invest
98:
62-69,
1996[ISI][Medline].
20.
Opie, LH.
Effects of regional ischemia on metabolism of glucose and fatty acids. Relative rates of aerobic and anaerobic energy production during myocardial infarction and comparison with effects of anoxia.
Circ Res
38:
I52-I74,
1976.
21.
Panchal, AR,
Comte B,
Huang H,
Kerwin T,
Darvish A,
Des Rosiers C,
Brunengraber H,
and
Stanley WC.
Partitioning of pyruvate between oxidation and anaplerosis in swine hearts.
Am J Physiol Heart Circ Physiol
279:
H2390-H2398,
2000
22.
Pantely, GA,
Malone SA,
Rhen WS,
Anselone CG,
Arai A,
Bristow J,
and
Bristow JD.
Regeneration of myocardial phosphocreatine in pigs despite continued moderate ischemia.
Circ Res
67:
1481-1493,
1990
23.
Peuhkurinen, KJ,
and
Hassinen IE.
Pyruvate carboxylation as an anaplerotic mechanism in the isolated perfused rat heart.
Biochem J
202:
67-76,
1982[ISI][Medline].
24.
Peuhkurinen, KJ,
Takala TE,
Nuutinen EM,
and
Hassinen IE.
Tricarboxylic acid cycle metabolites during ischemia in isolated perfused rat heart.
Am J Physiol Heart Circ Physiol
244:
H281-H288,
1983
25.
Pisarenko, OI,
Studneva IM,
Shulzhenko VS,
and
Kapelko VI.
Relations between the energy state of the myocardium and release of some products of anaerobic metabolism during underperfusion.
Pflügers Arch
416:
434-441,
1990[ISI][Medline].
26.
Rahimtoola, SH.
A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina.
Circulation
72:
123-135,
1985.
27.
Russell, RR, III,
Mommessin JI,
and
Taegtmeyer H.
Propionyl-L-carnitine-mediated improvement in contractile function of rat hearts oxidizing acetoacetate.
Am J Physiol Heart Circ Physiol
268:
H441-H447,
1995
28.
Russell, RR, III,
and
Taegtmeyer H.
Pyruvate carboxylation prevents the decline in contractile function of rat hearts oxidizing acetoacetate.
Am J Physiol Heart Circ Physiol
261:
H1756-H1762,
1991
29.
Schulz, R,
Guth BD,
Pieper K,
Martin C,
and
Heusch G.
Recruitment of an inotropic reserve in moderately ischemic myocardium at the expense of metabolic recovery. A model of short-term hibernation.
Circ Res
70:
1282-1295,
1992
30.
Schulz, R,
Post H,
Neumann T,
Gres P,
Luss H,
and
Heusch G.
Progressive loss of perfusion-contraction matching during sustained moderate ischemia in pigs.
Am J Physiol Heart Circ Physiol
280:
H1945-H1953,
2001
31.
Stanley, WC,
Hall JL,
Stone CK,
and
Hacker TA.
Acute myocardial ischemia causes a transmural gradient in glucose extraction but not glucose uptake.
Am J Physiol Heart Circ Physiol
262:
H91-H96,
1992
32.
Stanley, WC,
Hernandez LA,
Spires D,
Bringas J,
Wallace S,
and
McCormack JG.
Pyruvate dehydrogenase activity and malonyl-CoA levels in normal and ischemic swine myocardium: effects of dichloroacetate.
J Mol Cell Cardiol
28:
905-914,
1996[ISI][Medline].
33.
Stanley, WC,
Lopaschuk GD,
Hall JL,
and
McCormack JG.
Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions. Potential for pharmacological interventions.
Cardiovasc Res
33:
243-257,
1997
34.
Struck, E,
Ashmore J,
and
Wieland O.
Pyruvate carboxylase activity and glucose production in isolated perfused rat liver.
Enzymol Biol Clin (Basel)
7:
38-52,
1966[Medline].
35.
Sundqvist, KE,
Heikkila J,
Hassinen IE,
and
Hiltunen JK.
Role of NADP+ (corrected)-linked malic enzymes as regulators of the pool size of tricarboxylic acid-cycle intermediates in the perfused rat heart.
Biochem J
243:
853-857,
1987[ISI][Medline].
36.
Sundqvist, KE,
Hiltunen JK,
and
Hassinen IE.
Pyruvate carboxylation in the rat heart. Role of biotin-dependent enzymes.
Biochem J
257:
913-916,
1989[ISI][Medline].
37.
Tejero-Taldo, MI,
Caffrey JL,
Sun J,
and
Mallet RT.
Antioxidant properties of pyruvate mediate its potentiation of
-adrenergic inotropism in stunned myocardium.
J Mol Cell Cardiol
31:
1863-1872,
1999[ISI][Medline].
38.
Thomassen, AR,
Nielsen TT,
Bagger JP,
and
Henningsen P.
Myocardial exchanges of glutamate, alanine, and citrate in controls and patients with coronary artery disease.
Clin Sci (Lond)
64:
33-40,
1983[Medline].
39.
Vincent, G,
Comte B,
Poirier M,
and
Des Rosiers C.
Citrate release by perfused rat hearts: a window on mitochondrial cataplerosis.
Am J Physiol Endocrinol Metab
278:
E846-E856,
2000
40.
Williamson, JR,
and
Corkey BE.
Assays of intermediates of the citric acid cycle and related compounds by fluorometric enzyme methods.
In: Methods in Enzymology. New York: Academic, 1969, p. 434-516.
This article has been cited by other articles:
![]() |
M. Mayr Metabolomics: Ready for the Prime Time? Circ Cardiovasc Genet, October 1, 2008; 1(1): 58 - 65. [Full Text] [PDF] |
||||
![]() |
L. Zhou, H. Huang, T. A. McElfresh, D. A. Prosdocimo, and W. C. Stanley Impact of anaerobic glycolysis and oxidative substrate selection on contractile function and mechanical efficiency during moderate severity ischemia Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H939 - H945. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. C. Okere, T. A. McElfresh, D. Z. Brunengraber, W. Martini, J. P. Sterk, H. Huang, M. P. Chandler, H. Brunengraber, and W. C. Stanley Differential effects of heptanoate and hexanoate on myocardial citric acid cycle intermediates following ischemia-reperfusion J Appl Physiol, January 1, 2006; 100(1): 76 - 82. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Sabatine, E. Liu, D. A. Morrow, E. Heller, R. McCarroll, R. Wiegand, G. F. Berriz, F. P. Roth, and R. E. Gerszten Metabolomic Identification of Novel Biomarkers of Myocardial Ischemia Circulation, December 20, 2005; 112(25): 3868 - 3875. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. T. Mallet, J. Sun, E. M. Knott, A. B. Sharma, and A. H. Olivencia-Yurvati Metabolic Cardioprotection by Pyruvate: Recent Progress Experimental Biology and Medicine, July 1, 2005; 230(7): 435 - 443. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhou, J. E. Salem, G. M. Saidel, W. C. Stanley, and M. E. Cabrera Mechanistic model of cardiac energy metabolism predicts localization of glycolysis to cytosolic subdomain during ischemia Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2400 - H2411. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Sharma, I. C. Okere, D. Z. Brunengraber, T. A. McElfresh, K. L. King, J. P. Sterk, H. Huang, M. P. Chandler, and W. C. Stanley Regulation of pyruvate dehydrogenase activity and citric acid cycle intermediates during high cardiac power generation J. Physiol., January 15, 2005; 562(2): 593 - 603. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Khairallah, F. Labarthe, B. Bouchard, G. Danialou, B. J. Petrof, and C. Des Rosiers Profiling substrate fluxes in the isolated working mouse heart using 13C-labeled substrates: focusing on the origin and fate of pyruvate and citrate carbons Am J Physiol Heart Circ Physiol, April 1, 2004; 286(4): H1461 - H1470. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. C. Stanley Myocardial Energy Metabolism During Ischemia and the Mechanisms of Metabolic Therapies Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S31 - S45. [Abstract] [PDF] |
||||
![]() |
G. Vincent, B. Bouchard, M. Khairallah, and C. Des Rosiers Differential modulation of citrate synthesis and release by fatty acids in perfused working rat hearts Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H257 - H266. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lloyd, C. Brocks, and J. C. Chatham Differential modulation of glucose, lactate, and pyruvate oxidation by insulin and dichloroacetate in the rat heart Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H163 - H172. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Z. Martini, W. C. Stanley, H. Huang, C. D. Rosiers, C. L. Hoppel, and H. Brunengraber Quantitative assessment of anaplerosis from propionate in pig heart in vivo Am J Physiol Endocrinol Metab, February 1, 2003; 284(2): E351 - E356. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Comte, G. Vincent, B. Bouchard, M. Benderdour, and C. Des Rosiers Reverse flux through cardiac NADP+-isocitrate dehydrogenase under normoxia and ischemia Am J Physiol Heart Circ Physiol, October 1, 2002; 283(4): H1505 - H1514. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||